Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma

We present a case report of a male with multifocal and extensive basal cell carcinoma. Due to extremely large size and deep tumor infiltration, he was not a surgical candidate. Combined modality treatment of fractionated radiation with concurrent vismodegib was chosen. Concurrent treatment was previ...

Descripción completa

Detalles Bibliográficos
Autores principales: Franco, Abigail I., Eastwick, Gary, Farah, Ramsay, Heyboer, Marvin, Lee, Mijung, Aridgides, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841099/
https://www.ncbi.nlm.nih.gov/pubmed/29682362
http://dx.doi.org/10.1155/2018/2354146
_version_ 1783304697785876480
author Franco, Abigail I.
Eastwick, Gary
Farah, Ramsay
Heyboer, Marvin
Lee, Mijung
Aridgides, Paul
author_facet Franco, Abigail I.
Eastwick, Gary
Farah, Ramsay
Heyboer, Marvin
Lee, Mijung
Aridgides, Paul
author_sort Franco, Abigail I.
collection PubMed
description We present a case report of a male with multifocal and extensive basal cell carcinoma. Due to extremely large size and deep tumor infiltration, he was not a surgical candidate. Combined modality treatment of fractionated radiation with concurrent vismodegib was chosen. Concurrent treatment was previously reported in the palliative and recurrent setting. This is the first case of concurrent vismodegib and radiation therapy for upfront definitive management. The patient experienced complete response in all treated lesions.
format Online
Article
Text
id pubmed-5841099
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58410992018-04-21 Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma Franco, Abigail I. Eastwick, Gary Farah, Ramsay Heyboer, Marvin Lee, Mijung Aridgides, Paul Case Rep Dermatol Med Case Report We present a case report of a male with multifocal and extensive basal cell carcinoma. Due to extremely large size and deep tumor infiltration, he was not a surgical candidate. Combined modality treatment of fractionated radiation with concurrent vismodegib was chosen. Concurrent treatment was previously reported in the palliative and recurrent setting. This is the first case of concurrent vismodegib and radiation therapy for upfront definitive management. The patient experienced complete response in all treated lesions. Hindawi 2018-02-21 /pmc/articles/PMC5841099/ /pubmed/29682362 http://dx.doi.org/10.1155/2018/2354146 Text en Copyright © 2018 Abigail I. Franco et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Franco, Abigail I.
Eastwick, Gary
Farah, Ramsay
Heyboer, Marvin
Lee, Mijung
Aridgides, Paul
Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma
title Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma
title_full Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma
title_fullStr Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma
title_full_unstemmed Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma
title_short Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma
title_sort upfront radiotherapy with concurrent and adjuvant vismodegib is effective and well-tolerated in a patient with advanced, multifocal basal cell carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841099/
https://www.ncbi.nlm.nih.gov/pubmed/29682362
http://dx.doi.org/10.1155/2018/2354146
work_keys_str_mv AT francoabigaili upfrontradiotherapywithconcurrentandadjuvantvismodegibiseffectiveandwelltoleratedinapatientwithadvancedmultifocalbasalcellcarcinoma
AT eastwickgary upfrontradiotherapywithconcurrentandadjuvantvismodegibiseffectiveandwelltoleratedinapatientwithadvancedmultifocalbasalcellcarcinoma
AT farahramsay upfrontradiotherapywithconcurrentandadjuvantvismodegibiseffectiveandwelltoleratedinapatientwithadvancedmultifocalbasalcellcarcinoma
AT heyboermarvin upfrontradiotherapywithconcurrentandadjuvantvismodegibiseffectiveandwelltoleratedinapatientwithadvancedmultifocalbasalcellcarcinoma
AT leemijung upfrontradiotherapywithconcurrentandadjuvantvismodegibiseffectiveandwelltoleratedinapatientwithadvancedmultifocalbasalcellcarcinoma
AT aridgidespaul upfrontradiotherapywithconcurrentandadjuvantvismodegibiseffectiveandwelltoleratedinapatientwithadvancedmultifocalbasalcellcarcinoma

Ejemplares similares